<DOC>
	<DOCNO>NCT03061318</DOCNO>
	<brief_summary>A clinical trial propose , clinically validate diagnostic performance new genetic test develop Chile . It determine nature thyroid nodule inform indeterminate cytology fine needle aspiration ( FNA ) . The Genetic Classifier Indeterminate Thyroid Nodules quantitative gene expression test , combine result panel 10 biomarkers ( CXCR3 , CCR3 , CXCl10 , CK19 , TIMP1 , CLDN1 , CAR , XB130 , HO-1 CCR7 ) , generate single number score . It indicate patient thyroid nodule inform cytology indeterminate ( Bethesda III IV , accord The Bethesda System Reporting Thyroid Cytopathology ) . This test would use take sample fine needle aspiration ( FNA ) thus , able predict , high accuracy , benign nodule require surgery .</brief_summary>
	<brief_title>Validation Multi-Genetic Test Diagnosis Indeterminate Thyroid Nodules</brief_title>
	<detailed_description>Problem/Necessity : Throughout world , year , hundred thousand patient undergo unnecessary diagnostic surgery thyroid . This occur patient FNA inform indeterminate ( correspond 15-20 % FNA ) , due risk malignancy range 15 25 % . So , 75 % indeterminate nodule unnecessarily operate , make essential diagnostic tool allow u identify patient benign thyroid nodule thus , avoid surgery . Solution : We develop test , analysis expression 10 gene PCR real time FNA sample , integrate algorithm , rule presence cancer Negative Predictive Value ( NPV ) 96 % Specificity 81 % . Benefit/Justification : The high NPV allow clinician recommend observation alternative surgery . The 6 % false negative clinically accept due , cytology , 5 % false negative . On hand , 75 % specificity allow avoid surgery 75 % benign case , make test cost-effective . State Progress : The test complete phase prototype development analytical validation . The next stage clinical validation corresponds study propose protocol . Hypothesis : Our genetic test rule presence cancer NPV high 94 % Specificity high 75 % indeterminate nodule sample . Proposed study : A multi-centric ( 9 site ) clinical trial develop Chile , statistical power determine sensitivity clinical specificity , negative positive predictive value , likelihood ratio confidence interval . Method : Patients FNA indicate treat physician , due indeterminate nodule require determined benign malignant , invite participate trial . After informed consent sign , FNA sample obtain cytology molecular study . Obtaining sample molecular study part procedure . A maximum 4000 sample must enrol . Approximately 300 fulfill requirement complete study , include : confirmed indeterminate cytology , send surgery ( gold standard ) , proper mRNA sample . Throughout study , treat physician modify conduct time decision base clinical information regularly use . Timeline/Monitoring : The study recruitment phase expect last approximate 28 month ( 24 month enrollment , 4 month follow minimum time obtain result surgical biopsy ) . However , timeline might extend wait 300 indeterminate sample end study . There principal investigator site , guide hire CRO , guard correct execution trial .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Nodule</mesh_term>
	<criteria>Patient ≥ 18 year old , male female Patent thyroid nodule ≥ 8.0 mm diameter measure ultrasound . Patient indication thyroid fine needle aspiration ( FNA ) . Patient record spontaneous bleeding . Patient condition understand sign ICF . 1 . Patient &lt; 18 year old , male female . 2 . Patient ultrasound diagnosis thyroid nodule &lt; 8.0 mm . 3 . Patient record spontaneous bleeding . 4 . Patient current symptom bleed . 5 . Patient condition understand sign ICF .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Fine Needle Aspiration , Genetic Classifier</keyword>
</DOC>